Form Type: 4

SEC EDGAR Link
Accession Number:0001439222-21-000077
Date:2021-12-02
Issuer: AGIOS PHARMACEUTICALS, INC. (AGIO)
Original Submission Date:

Reporting Person:

GHEUENS SARAH
88 SIDNEY STREET
CAMBRIDGE, MA 02139

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2021-12-02 M 834 a $0.00 4,296 direct
COMMON STOCK 2021-12-02 F 248 d $35.00 4,048 direct
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
RESTRICTED STOCK UNITS 0.0 2021-12-02 deemed execution date M 834 (d) common stock 834 $0.00 833 direct
Footnotes
IDfootnote
f1 each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
f2 the restricted stock units were granted on december 2, 2019. beginning on december 2, 2020, the shares underlying the restricted stock units will vest in three equal annual installments.

Elevate your investments